|Target||Interleukin 17 receptor A|
|Synonyms||KHK4827, AMG 827|
|Chemical and physical data|
|Molar mass||144.06 kg/mol|
|(what is this?)|
Mechanism of action
Brodalumab binds to the interleukin-17 receptor and so prevents interleukin 17 (IL-17) from activating the receptor. (This mechanism is similar to that of another anti-psoriasis antibody, ixekizumab, which however binds to IL-17 itself.)
Brodalumab was developed by Amgen, Inc. as AMG 827.
In November 2014, Amgen and AstraZeneca reported encouraging results for the compound. The companies stated that the compound met the primary endpoint showing superior skin clearance in a Phase III trial when compared to ustekinumab and a placebo.
However, in May 2015, Amgen announced that it was ending its participation in co-development of the compound because of reports of patients having "events of suicidal ideation and behavior". AstraZeneca will be solely responsible for any future development and marketing of brodalumab in all territories except for certain Asian territories such as Japan, where Kyowa Hakko Kirin has rights to brodalumab and continued as KHK4827.
In September 2015, AstraZeneca announced a partnership with Valeant Pharmaceuticals in which Valeant took over exclusive rights to develop and commercialize brodalumab. In July 2016, the rights to commercialize brodalumab in Europe were sold to LEO Pharma.
- "Statement On A Nonproprietary Name Adopted By The USAN Council: Brodalumab" (PDF). American Medical Association.
- EMA CHMP opinion on Kyntheum. May 2017
- Commissioner, Office of the (15 February 2017). "Press Announcements - FDA approves new psoriasis drug". www.fda.gov. Retrieved 18 February 2017.
- Clinical trial number NCT01708590 for "Study of Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab in Moderate to Severe Plaque Psoriasis Subjects (AMAGINE-1)" at ClinicalTrials.gov
- Clinical trial number NCT01708629 for "Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects (AMAGINE-3)" at ClinicalTrials.gov
- "Amgen to terminate participation in co-development and commercialization of brodaluma". Amgen.
- FDA accepts AstraZeneca's brodalumab BLA for plaque psoriasis, PDUFA date November 16Valeant Announces FDA Acceptance of BLA Submission for Brodalumab in Moderate-to-Severe Plaque Psoriasis. Jan 2016
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|
|This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.|